跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 5,721 条关于
“TAK-594/DNL593”
全部
5,721
临床试验
4,368
药物
851
机构
49
资讯
453
3年前
Novel Gene Therapies and Biomarkers Advance the Fight Against Frontotemporal Dementia
2年前
Denali Therapeutics Announces Positive Clinical Updates and Financial Results for Q1 2024
去年
Frontotemporal Dementia Therapeutics Enter New Era as Gene and Antibody Therapies Advance Toward Market
去年
Japanese Dengue Vaccine TAK-003 Approved for Use in Argentina
2年前
Takeda's TAK-861 Shows Promising Results in Phase 2b Trial for Narcolepsy Type 1
上个月
China Becomes First Globally to Approve Takeda's Novel Narcolepsy Drug TAK-861
去年
Takeda's Oral TYK2 Inhibitor TAK-279 Shows Promising Efficacy in Psoriasis Treatment
去年
Denali and Takeda Open FTD-GRN Clinical Trial Site at UPenn
2年前
Takeda Advances TAK-861 to Phase III for Narcolepsy Type 1 Following Positive Phase IIb Results
去年
TAK-071 Shows Mixed Results in Parkinson's Disease Trial: Cognitive Benefits Observed Despite Missing Primary Endpoint
第 1 页,共 46 页
上一页
下一页